Basel, 02 September 2019 Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86% BLOCKSTONE study reaches primary endpoint of fewer people testing positive for flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placebo Xofluza may represent an important and... Read more
Basel, 02 September 2019 Roche presents positive phase III study results for one-dose Xofluza in children with flu Phase III MINISTONE-2 data are consistent with known safety profile of Xofluza (baloxavir marboxil) in children and show comparable efficacy to oseltamivir Xofluza was administered as a new one-dose oral suspension, a potentially more convenient treatment option... Read more
Basel, 29 August 2019 Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq This launch represents an important step in Roche’s personalised healthcare strategy to fit treatments to patients who can benefit most from a specific medicine Each year 300,000... Read more
Basel, 29 August 2019 European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for triple-negative breast cancer – an aggressive and difficult-to-treat disease Approval based on the Phase III IMpassion130 study, which showed... Read more
Basel, 16 August 2019 FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Roche’s first FDA-approved tumour-agnostic medicine Roche (SIX: RO, ROG;... Read more
Basel, 05 August 2019 Roche’s Tecentriq plus platinum-based chemotherapy reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer Data will be shared with health authorities globally, including the U.S.... Read more
Basel, 31 July 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares... Read more
Basel, 26 July 2019 Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer Decision based on data showing that the Tecentriq plus chemotherapy combination demonstrated a significant overall survival (OS) and progression-free survival (PFS) benefit in the first-line treatment of people with... Read more
Basel, 26 July 2019 CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer Decision based on results from first Phase III study to show a cancer immunotherapy-based combination significantly improved overall survival (OS) and progression-free survival (PFS) in over 20 years... Read more
Basel, 22 July 2019 Roche expands the Global Access Program beyond HIV to also include diagnostic tests for Tuberculosis, Hepatitis, and Human Papillomavirus Access to innovative diagnostic solutions will contribute to the World Health Organization’s infectious disease elimination goals Improving access to reliable diagnostics for disease management in countries with the highest burden Early detection... Read more